cancer - International Biopharmaceutical Industry

news

Roche’s top immunotherapy prospect fails study in tough-to-treat lung cancer

Dive Brief: A drug combination including the Roche immunotherapy tiragolumab failed a Phase 3 trial in a tough-to-treat form of lung cancer, a setback for a closel...

1 April 2022 news cancer | Drug

Continue Reading →

news

How Merck’s ‘puzzling’ results could impact immunotherapy’s role in early lung cancer

An immunotherapy from Merck & Co. is the latest drug of its kind to slow the return of lung cancer in clinical testing, though mixed results in the large study su...

21 March 2022 news cancer | immunotherapy

Continue Reading →

news

FDA sets back Karyopharm’s bid to broaden use of cancer drug

Dive Brief: Karyopharm Therapeutics will have to perform a new clinical trial to widen the use of its cancer drug selinexor after U.S. regulators said the results ...

4 March 2022 news cancer | Drug

Continue Reading →

news

AstraZeneca, Daiichi press rivals with new results for breast cancer drug

Dive Brief: AstraZeneca and Daiichi Sankyo's antibody drug Enhertu could become standard treatment for a large group of breast cancer patients following Phase 3 st...

24 February 2022 news AstraZeneca | breast

Continue Reading →

news

Why the FDA is making a test case of a cancer drug from China

At a quick glance, the Food and Drug Administration's decision to ask its advisers for help in vetting yet another cancer immunotherapy may seem odd. After all, the ...

10 February 2022 news cancer | china

Continue Reading →

news

Pressure rises as Gilead awaits important study results for top cancer drug

Gilead lost several billion dollars in market value Wednesday after unnerving investors with updates about a key clinical trial of its most closely watched breast can...

10 February 2022 news cancer | clinical

Continue Reading →

news

Pressure rises as Gilead awaits important study results for top cancer drug

Gilead lost several billion dollars in market value Wednesday after unnerving investors with updates about a key clinical trial of its most closely watched breast can...

6 February 2022 news cancer | Drug

Continue Reading →

news

A biotech wins the first FDA drug approval in a rare type of eye cancer

Dive Brief: The Food and Drug Administration on Tuesday granted approval to the first drug for a rare cancer of the eye that has spread elsewhere or grown too larg...

27 January 2022 news Biotech | cancer

Continue Reading →

news

Incyte withdraws cancer drug from FDA review after discussions with regulator

Dive Brief: Incyte is pulling its application for an experimental lymphoma medicine after determining that the Food and Drug Administration's requirements for conf...

27 January 2022 news cancer | Drug

Continue Reading →

news

EQRx builds case for cancer drug it hopes can disrupt market

Dive Brief: EQRx, which aims to bring new medicines to market at "radically lower" prices, said the experimental lung cancer drug it co-owns with Chinese biotech C...

20 January 2022 news cancer | Drug

Continue Reading →